Targeting angiogenesis in head and neck cancer

Maria Vassilakopoulou, Amanda Psyrri, Athanassios Argiris

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Angiogenesis is a crucial step in tumor growth and metastasis. Head and neck squamous cell carcinomas (HNSCC) highly express angiogenesis factors, such as vascular endothelial growth factor (VEGF), which are associated with patient prognosis. Antiangiogenesis agents can potentially modulate tumor microenvironment and induce radiosensitivity and chemosensitivity. In this review, we discuss the molecular mechanisms underlying angiogenesis involved in HNSCC, preclinical data with antiangiogenesis agents as well as potential predictive biomarkers. We also review novel therapies under investigation and summarize the results of clinical trials using antiangiogenesis agents alone or in combination with conventional therapies in HNSCC.

Original languageEnglish (US)
Pages (from-to)409-415
Number of pages7
JournalOral Oncology
Issue number5
StatePublished - 2015


  • Angiogenesis
  • Bevacizumab
  • Head and neck cancer
  • Monoclonal antibodies
  • Targeted therapy
  • Tyrosine kinase inhibitors
  • Vascular endothelial growth factor
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research


Dive into the research topics of 'Targeting angiogenesis in head and neck cancer'. Together they form a unique fingerprint.

Cite this